Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements

Leukemia

Volumn 17, Issue 4, 2003, Pages 700-706

  Pui, C H ^a,b   Chessells, J M ^c   Camitta, B ^c   Baruchel, A ^c   Biondi, A ^c   Boyett, J M ^a,b   Carroll, A ^c   Eden, O B ^c   Evans, W E ^a,b   Gadner, H ^c   Harbott, J ^c   Harms, D O ^c   Harrison, C J ^c   Harrison, P L ^a,b   Heerema, N ^c   Janka Schaub, G ^c   Kamps, W ^c   Masera, G ^c   Pullen, J ^c   Raimondi, S C ^a,b   Richards, S ^c   Riehm, H ^c   Sallan, S ^c   Sather, H ^c   Shuster, J ^c   Silverman, L B ^c   Valsecchi, M G ^c   Vilmer, E ^a,b   Zhou, Y ^a,b   Gaynon, P S ^c   Schrappe, M ^c   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NONE

Author keywords

11q23; Acute lymphoblastic leukemia; Infant leukemia; MLL rearrangement; t(11; 19); t(4; 11); Transplantation

Indexed keywords

METHOTREXATE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ANALYTIC METHOD; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL LINEAGE; CHILD; CHILDHOOD CANCER; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 4; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENETIC HETEROGENEITY; GROUPS BY AGE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0242500374     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402883     Document Type: Article

References (41)

1. Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9: 762-769.
2. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24-33.
3. Pui CH. Acute leukemias with the t(4;11)(q21;q23). Leukemia Lymphoma 1992; 7: 173-179.
4. Pui CH, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood 1991; 77: 440-447.
5. Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S et al. Hematologic malignancies with t(4;11)(q21;q23) - a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia 1998; 12: 779-787.
6. Rubnitz JE, Camitta BM, Mahmoud H, Raimondi SC, Carroll AJ, Borowitz MJ et al. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. J Clin Oncol 1999; 17: 191-196.
7. Moorman AV, Hagemeijer A, Charrin C, Rieder H, Secker-Walker LM. The translocations, t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3): a cytogenetic and clinical profile of 53 patients. European 11q23 Workshop participants. Leukemia 1998; 12: 805-810.
8. Forestier E, Johansson B, Gustafsson G, Borgström G, Kerndrup G, Johannsson J et al. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group. Br J Haematol 2000; 110: 147-153.
9. Chen CS, Sorensen PH, Domer PH, Reaman GH, Korsmeyer SJ, Heerema NA et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81: 2386-2393.
10. Ferster A, Bertrand Y, Benoit Y, Boilletot A, Behar C, Margueritte G et al. Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC-Childhood Leukaemia Cooperative Group. Br J Haematol 1994; 86: 284-294.
11. Pui CH, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12: 909-915.
12. Rubnitz JE, Link MP, Shuster JJ, Carroll AJ, Hakami N, Frankel LS et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1994; 84: 570-573.
13. Cimino G, Rapanotti MC, Rivolta A, Lo Coco F, D'Arcangelo E, Rondelli R et al. Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia 1995; 9: 391-395.
14. Taki T, Ida K, Bessho F, Hanada R, Kikuchi A, Yamamoto K et al. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 1996; 10: 1303-1307.
15. Heerema NA, Arthur DC, Sather H, Albo V, Feusner J, Lange BJ et al. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group. Blood 1994; 83: 2274-2284.
16. Heerema NA, Sather HN, Ge J, Arthur DC, Hilden JM, Trigg ME et al. Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11)- a report of the Children's Cancer Group. Leukemia 1999; 13: 679-686.
17. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915.
18. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24.
19. Stram DO, Sather H, Wang L. Analysis of time to death after transplantation when transplants are only given to patients in remission. Biometrics 1996; 52: 1079-1086.
20. Pui C-H, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-615.
21. Aricó M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
22. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445-455.
23. Dördelmann M, Reiter A, Borkhardt A, Ludwig WD, Götz N, Viehmann S et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217.
24. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia - current status and future perspectives. Lancet Oncol 2001; 2: 597-607.
25. Pui CH, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990; 75: 174-179.
26. Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC, Chessells JM et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia 2000; 14: 2307-2320.
27. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000; 14: 2276-2285.
28. Pui CH, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC et al. Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14: 2286-2294.
29. Huret JL, Brizard A, Slater R, Charrin C, Bertheas MF, Guilhot F et al. Cytogenetic heterogeneity in t(11;19) acute leukemia: clinical, hematological and cytogenetic analyses of 48 patients - updated published cases and 16 new observations. Leukemia 1993; 7: 152-160.
30. Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR et al. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996; 87: 2870-2877.
31. Raimondi SC, Frestedt JL, Pui CH, Downing JR, Head DR, Kersey JH et al. Acute lymphoblastic leukemias with deletion of 11q23 or a novel inversion (11)(p13q23) lack MLL gene rearrangements and have favorable clinical features. Blood 1995; 86: 1881-1886.
32. Harbott J, Mancini M, Verellen-Dumoulin C, Moorman AV, Secker-Walker LM. Hematological malignancies with a deletion of 11q23: cytogenetic and clinical aspects. European 11q23 Workshop participants. Leukemia 1998; 12: 823-827.
33. Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol 2002; 117: 306-314.
34. Locatelli F, Zecca M, Messina C, Rondelli R, Lanino E, Sacchi N et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002; 16: 2228-2237.
35. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898-1909.
36. Silverman LB, McLean TW, Gelber RD, Donnelly MJ, Gilliland DG, Tarbell NJ et al. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer 1997; 80: 2285-2295.
37. Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - implications for treatment of infants. Leukemia 1998; 12: 1344-1348.
38. Dreyer ZE, Steuber CP, Bowman WP, Murray JC, Coppes MJ, Dinndorf P et al. High risk infant ALL-improved survival with intensive chemotherapy. Proc Am Soc Clin Oncol 1998; 17: 529a.
39. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47.
40. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885-3891.
41. Tse K-F, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002; 16: 2027-2036.